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ABSTRACT 29 
Previous research has shown that resveratrol is able to increase cerebral blood flow (CBF) in the 30 
absence of improved cognitive performance, in healthy, young humans during cognitively 31 
demanding tasks. This lack of cognitive effects may be due to low bioavailability and, in turn, 32 
reduced bioefficacy of resveratrol in vivo. Piperine is able to alter polyphenol pharmacokinetics but 33 
previous studies have not investigated whether this affects the efficacy of the target compound. 34 
Taken together, the objective here was to ascertain if piperine co-supplementation might affect the 35 
bioavailability and efficacy of resveratrol with regards cognition and CBF. This investigation 36 
utilized a randomised, double-blind, placebo-controlled, within subjects design, where 23 adults 37 
received placebo, trans-resveratrol (250mg), and trans-resveratrol with 20mg piperine, on separate 38 
days at least a week apart. After a 40min rest/absorption, participants performed a selection of 39 
cognitive tasks and CBF was assessed throughout, in the frontal cortex, using Near-Infrared 40 
Spectroscopy (NIRS). The presence of resveratrol and its conjugates in plasma were confirmed by 41 
LC-MS following the same doses in a separate cohort (N=6). The results indicated that when co-42 
supplemented, piperine and resveratrol significantly augmented CBF during task performance in 43 
comparison to placebo and resveratrol alone. Cognitive function, mood and blood pressure were not 44 
affected. Plasma levels of resveratrol and its metabolites were not significantly different between 45 
treatments which indicates that piperine co-supplementation enhances the bioefficacy of resveratrol 46 
with regards CBF effects, but not cognitive performance, and does this without altering 47 
bioavailability.  48 
 49 
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INTRODUCTION 59 
Resveratrol (3, 4’, 5 trihydroxystilbene) is a polyphenolic secondary metabolite produced within 60 
plants in response to a range of environmental stressors 
(1)
. Resveratrol ingestion has also been 61 
shown to have protective effects in animals and humans. Of direct relevance here, these effects 62 
include a protection of cognitive function/reversal of cognitive deficits in animal models following 63 
supplementation 
(2)
 which may, in large part, be due to the cerebral blood flow (CBF) effects 64 
evinced by resveratrol 
(3)
. These CBF effects are likely to be mediated by the ability of resveratrol to 65 
modulate nitric oxide (NO) synthesis 
(4)
, with oral intervention shown to enhance endothelium-66 
dependent relaxation in rats 
(5, 6)
, and improve flow- mediated dilatation in overweight/obese 67 
humans 
(7)
. An increase in blood-borne neural metabolic substrates such as oxygen 
(8)
 and glucose 
(9)
 68 
is reported to enhance aspects of cognitive performance in healthy, young humans. Taken together, 69 
it could be hypothesized that an acute increase in CBF, augmenting the delivery of metabolic 70 
substrates, might also beneficially affect cognitive performance. 71 
A recent study from this laboratory demonstrated a dose-related increase in pre-frontal cortex CBF 72 
during cognitively demanding tasks in healthy, young adults. This effect was consistent across all 73 
time points for 500mg, but failed to reach significance for 250mg of resveratrol. The increase in 74 
CBF did not facilitate improved cognitive task performance 
(10)
. It was argued that this may be due 75 
to low bioavailability of resveratrol.  76 
The pepper derived alkaloid piperine has been observed to be a potent enhancer of the 77 
bioavailability of numerous compounds, including polyphenols, in vivo; for instance, 78 
epigallocatechin-3-gallate (EGCG) in rodents 
(11)
, curcumin in rats and humans 
(12)
, and beta-79 
carotene following 14-days co-supplementation in humans 
(13)
. With regards resveratrol, piperine 80 
co-supplementation (10mg/kg) is reported to evince a 1544% enhancement of maximum serum 81 
resveratrol levels (compared to 100mg/kg resveratrol alone) and increase exposure (AUC) by 229% 82 
in mice 
(14)
. Potential mechanisms for these phenomena include inhibition of enzymes responsible 83 
for metabolising polyphenols 
(14-16)
; enhancement of metabolism via thermogenic effects 
(13)
; and/or 84 
competing for membrane efflux pumps in the body and brain: a phenomena seen when plant 85 
derived compounds are co-administered, for example polyphenols 
(17)
. These studies, however, did 86 
not investigate whether increased bioavailability led to increased bioefficacy of the target 87 
compound. 88 
The current randomised, double-blind, placebo-controlled, cross-over study therefore investigated 89 
the effects of 250mg resveratrol when administered alone, and when co-supplemented with 20mg of 90 
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piperine. The rationale for utilizing 250mg resveratrol here is based on the previous ineffectiveness 91 
of this dose in modulating CBF and the expectation that this will be augmented by the actions of 92 
piperine. The aim was to ascertain if piperine is capable of enhancing the bioefficacy of resveratrol 93 
with regards CBF and cognitive performance in healthy adults. Blood plasma levels of resveratrol 94 
were collected to investigate whether bioavailability correlated with bioefficacy. 95 
 96 
 97 
EXPERIMENTAL METHODS 98 
Participants (CBF and cognitive performance assessment): 99 
23 healthy adults (4 males, 19 females, mean age 21yrs, range 19-34yrs, SD 3.2yrs, all right 100 
handed) took part in all three arms of the cross-over study. The data from 1 participant was 101 
excluded from analysis due to data catchment errors. All participants attended the laboratory after a 102 
12hr overnight fast and reported to meet the inclusion criteria: i.e. to be in good health and free 103 
from social drugs, alcohol, prescription medication, herbal extracts/food supplements, relevant food 104 
allergies, intolerances and digestive problems. A fasted state was considered to be most appropriate 105 
due to the individual differences involved with breakfast consumption and the unknowns involved 106 
with the absorption of resveratrol together with food. Whilst food deprivation has been reported to 107 
deleteriously affect cognitive function previously in children 
(18, 19)
 actually more recent research 108 
with athletes during Ramadan is more ambiguous 
(20)
 and a well-controlled study of healthy, young 109 
adults finds no detrimental effects of fasting on cognitive performance 
(21)
. All participants were 110 
non-smokers and did not consume excessive amounts of caffeine (>6 cups of coffee or 111 
equivalent/d). In addition, participants who had suffered a head injury, neurological disorder or 112 
neuro-developmental disorder were excluded from participation, as were those who had uncorrected 113 
sight problems, were pregnant or seeking to become so. 114 
 115 
Participants (Bioavailability analysis): 116 
6 healthy (mean BMI 24.2, range 21.7-27.2, SD 2.38) male adults (mean age 25.8yrs, range 23-117 
29yrs) took part in the bioavailability assessment. Inclusion/exclusion criteria were as per the CBF 118 
and cognitive performance aspect of the study. 119 
This study was conducted according to the guidelines laid down in the Declaration of Helsinki and 120 
all procedures involving human subjects were approved by the department of Psychology ethics 121 
committee at Northumbria University. Written informed consent was obtained from all subjects. 122 
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Treatments: 123 
During the three study visits participants received three single-dose treatments in an order dictated 124 
by random allocation to a counterbalancing (Latin Square) order. The three treatments comprised 125 
two capsules; each combination delivering either an inert placebo, 250mg of trans-resveratrol or 126 
250mg of trans-resveratrol plus 20mg piperine. The treatments were administered in identical size 0 127 
vegetable capsules, which were prepared by the lead researcher and coded by a third party who had 128 
no further involvement in any aspect of the study. No member of the investigational team was 129 
aware of the contents of the capsules until a blind-data review was completed. 130 
 131 
Near-Infrared spectroscopy (NIRS): 132 
Relative changes in the absorption of near-infrared light were measured at a time resolution of 10Hz 133 
using a 12-channel Oxymon system (Artinis Medical Systems B.V.). The system emitted two 134 
nominal wavelengths of light (~765- and 855nm) with an emitter/optode separation distance of 135 
4cm. The differential pathlength factor was adjusted according to the age of the participant. Relative 136 
concentration changes in oxy-Hb, deoxy-Hb and total-Hb were calculated by means of a modified 137 
Beer-Lambert law 
(22)
 using the proprietorial software. Given the extended recording period and the 138 
investigational aims, a simple two emitter/optode pair configuration was utilised (i.e. 2 channels). 139 
The emitter/optode pairs were positioned over the left and right frontal cortex using a standard 140 
optode holder headband, which separated the pairs from each other by 4cm. Each pair therefore 141 
collected data from an area of prefrontal cortex that included the areas corresponding to the 142 
International 10-20 system Fp1 and Fp2 EEG positions. The NIRS data output was time stamped at 143 
the start of each task segment to assure that data corresponded to the relevant epoch of task 144 
performance. 145 
 146 
Cognitive tasks: 147 
In order to maximise cerebral activity-induced modulation of blood flow, a pilot study was initially 148 
carried out with a separate cohort of 15 participants (3 male, 12 female, mean age 21.6yrs, all right 149 
handed) to ascertain the most ‘mentally demanding’ and ‘difficult’ tasks from a battery of 11. (Data 150 
not reported.) The 5 tasks utilized here were all subjectively rated as both the most ‘demanding’ and 151 
most ‘difficult’ and have all previously been shown to activate the frontal cortex in fMRI studies (23-152 
25)
. The computerised battery of cognitive tasks were delivered using the Computerised Assessment 153 
of Mental Performance System (COMPASS) software, and comprised:  154 
 155 
 156 
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Serial subtractions (2 mins each of serial 7s, 13s and 17s):  157 
Rapid Visual Information Processing [RVIP] (2 mins):  158 
Both the serial subtraction task and RVIP are described in detail in 
(10)
. 159 
 160 
N-back: The 3-back version of this task was used in this paradigm, requiring participants to 161 
indicate whether the letter presented on screen was also present 3 letters back in the letter sequence. 162 
Participants must respond by pressing the ‘yes’ or ‘no’ button on the response box, to each letter, as 163 
quickly as they can. This task includes sufficient stimuli (letters) to last for at least 2 minutes 164 
although this is dependent on speed (i.e. slower reaction times will result in a lengthier task) and is 165 
scored for accuracy and reaction time. 166 
 167 
Mood Visual Analogue Scales (Mood VAS): Participants were required to rate how ‘relaxed’, 168 
‘alert’, ‘jittery’, ‘tired’, ‘tense’ and ‘mentally fatigued’ they felt by placing a cross with the mouse 169 
and cursor on a 100mm on-screen line between the descriptors ‘not at all’ and ‘extremely’. They 170 
also rated their ‘overall mood’ on a scale anchored by ‘very poor’ to ‘very good’ and their levels of 171 
‘headache’ between ‘not at all’ and ‘extremely’. The VAS were scored as % along the line denoting 172 
more of the relevant adjective. 173 
 174 
Procedure (CBF and cognitive performance assessment): 175 
Each participant was required to attend the laboratory on 4 occasions. The first of these was an 176 
initial screening/training visit during which participants provided written informed consent, were 177 
screened with regards the study inclusion/exclusion criteria, briefed with regards compliance 178 
requirements and given training in completing the cognitive tasks. This visit was followed within 14 179 
days by the first of 3 active study mornings.  180 
On each of the 3 active study mornings, which were conducted 2-14 days apart, participants 181 
attended the laboratory at 8:30am in a fasted state and provided confirmation of continued 182 
compliance with regards the inclusion/exclusion requirements. After a 5 minute seated resting 183 
period a blood pressure reading was taken after which the NIRS headband was fitted. Participants 184 
then completed a series of mood VAS and 2 repetitions of baseline cognitive tasks in the following 185 
order: Serial 7s, RVIP, Serial 13s, N-Back, and Serial 17s. Participants then rested for 10 minutes 186 
and provided a 2
nd
 blood pressure reading. Treatment was then administered after which 187 
participants sat quietly, watching one of a selection of non-arousing DVDs, for a 40 minute 188 
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‘absorption’ period. Following this time a 3rd blood pressure reading was taken after which 189 
participants completed 4 repetitions of the aforementioned tasks in the same order and duration. 190 
After the post dose tasks were completed the same mood VAS were presented and the 4
th
 and final 191 
blood pressure reading was taken. NIRS data was captured throughout. The timeline and running 192 
order of the testing session are shown in Figure 1.  193 
 194 
Figure 1. Testing session timeline. Upon arrival participants rested for 5-min before the 1
st
 blood pressure 195 
reading was taken. The NIRS headband was then fitted. Mood visual analogue scales (VAS) and 2 196 
repetitions of baseline cognitive tasks were completed and followed by a 10-min rest. The 2
nd
 blood pressure 197 
reading was then taken and treatment was administered. After a 40-min absorption period the 3
rd
 blood 198 
pressure reading was taken. 4 repetitions of the cognitively demanding tasks were then completed, followed 199 
by mood VAS and the 4
th
 and final blood pressure.  200 
 201 
Procedure (bioavailability assessment):   202 
On each study morning participants attended the laboratory at 8.30am. Venous blood samples were 203 
collected using 4.7ml monovettes (containing lithium heparin) before the day’s treatment was 204 
consumed and then 45-, 90- and 120 minutes after consuming intervention. Samples were 205 
centrifuged at 2500rpm for 15min at 20
o
C to yield plasma, which was then stored at -80
o
C until 206 
analysis.  207 
 208 
Preparation of Samples: 209 
Samples were handled in low light conditions to reduce the scope for isomerisation. Plasma was 210 
defrosted at room temperature immediately before extraction, vortexed then sonicated for 5min. A 211 
200L aliquot was mixed with 900L of HPLC grade ethanol plus 0.1% formic acid (v/v), along 212 
with 100L of naringenin internal standard (IS1; Extrasynthese, France) in ethanol (500ng/ml). 213 
Samples were vortexed, sonicated and then separated via micro-centrifugation at 17k R.C.F. for 214 
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10min. The supernatant was removed and placed in an amber 1.5ml centrifuge tube (Eppendorf, 215 
UK). The pellet was re-extracted with 1.2ml of 83% aqueous ethanol (v/v) following the same 216 
protocol. Both extracts were evaporated to dryness under vacuum using a centrifugal evaporator 217 
(EZ2+, Genevac, UK), and frozen at -20
o
C. On the day of analysis, a 70L portion of ethanol was 218 
added to the secondary extract, which was vortexed and sonicated. A 50L aliquot of this solution 219 
was then added to the primary extract, which following vortexing and sonication was mixed with 220 
50L taxifolin (IS2 at 2g/ml; Extrasynthese, France) in 0.2% ascorbic acid solution. This solution 221 
was vortexed, separated by centrifugation and the supernatant placed in an amber vial and analyzed 222 
via LC-MS. Extractions were made in duplicate for each time point. To test extraction efficiency of 223 
this method, blank plasma was spiked with standards at 50nM, 500nM, 5M and 10M 224 
concentrations. Across this range, the average extraction efficiencies for trans-resveratrol (Cayman 225 
Chemicals, USA), the -3-O-sulfate, 4-O’-glucuronide and 3-O-glucuronide (Bertin Pharma, France) 226 
were 74%, 72%, 52% and 55%, respectively. IS1 and IS2 were extracted consistently at 82% and 227 
100%, respectively.  228 
 229 
LC-MS Analysis: 230 
Analysis was conducted using a Shimadzu LC2010CHT HPLC, consisting of an integrated 231 
quaternary pump, degasser, chilled autosampler (8
o
C), and column oven (30
o
C), connected to an 232 
LCMS2020 single quadrupole mass spectrometer. A 10L sample aliquot was separated on an 233 
XDB–C18 1.84.6 x 50mm column (Agilent, UK), running a binary gradient of LCMS grade 234 
water vs. acetonitrile, both containing 0.1% formic acid (v/v), running at 0.5ml/min. The gradient 235 
started at 5% acetonitrile, and moved to 10% at 5min, 40% at 20min and 90% at 25min. Following 236 
4min of washing, the column returned to 5% acetonitrile at 30min and was re-equilibrated over 237 
3min. The MS ran with an interface temperature set to 350
o
C, using nebuliser and drying gas flow 238 
rates of 1.5- and 15L/min, respectively. The analysis was performed in negative SIM mode, 239 
following m/z of 403 (glucuronides), 307 (sulfates) 271 (naringenin IS1), 303 (taxifolin IS2) and 240 
227 (aglycone resveratrol). A persistent formate adduct of aglycone resveratrol (m/z 273) was also 241 
followed as a qualifying ion. The limit of quantification (LOQ) for glucurnoides was 16nM, 22nM 242 
for sulfates, and 145nM and 290nM for cis- and trans-aglycone resveratrol respectively. Peak areas 243 
were normalized to IS2 for quantification, whilst IS1 was used to judge individual sample 244 
extraction. The retention times of cis-isomer resveratrol conjugates were identified by subjecting 245 
commercially available trans-isomers (10 µg/ml in 50% aqueous ethanol, plus 0.1% ascorbic and 246 
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0.05% formic acids) to ultraviolet light (254 nm) for 4 hr. Cis-isomer resveratrol conjugates were 247 
quantified as trans- isomer equivalents, and then summed with the corresponding trans- isomers.   248 
 249 
Statistics: 250 
The analyses of plasma data was conducted with SPSS 16.0 for Windows (SPSS Inc, Chicago, IL) 251 
utilizing within subjects analysis of variance (ANOVA) (treatment x time) for each metabolite and 252 
paired samples t-tests to compare AUC, Cmax and Tmax, between the 2 treatments, for each 253 
metabolite. 254 
NIRS data was analysed with Minitab 16 for Windows (Minitab Inc, State College, PA). For each 255 
variable (oxy-Hb, deoxy-Hb and total-Hb), data was converted to ‘change from baseline’ 256 
(calculated from a 10 minute pre-treatment resting period) and averaged across 2 minute epochs 257 
during the 40 minute ‘rest/absorption’ and 40 minute cognitive task performance period. Analysis 258 
was based on an average of the 2 NIRS channels to give a measure of cerebral hemodynamics 259 
across the prefrontal cortex as a whole; in line with 
(10)
.  260 
The primary analysis of the averaged NIRS data was conducted by within-subjects ANOVA 261 
(treatment x 2 min epoch) with a priori planned comparisons of data from each epoch being made 262 
between placebo and each of the resveratrol treatment groups (250mg resveratrol, 250mg 263 
resveratrol with 20mg piperine) using t-tests calculated with the Mean Squares Error from the 264 
ANOVA 
(26)
. In order to protect against the possibility of type 1 errors, planned comparisons are 265 
only reported if they evinced a consistent pattern of significant effects across the analysis period.  266 
Task performance data (also analysed with SPSS 16.0) was analysed as change from pre-dose 267 
baseline for each individual task (Serial 7s, RVIP, Serial 13s, 3-back and Serial 17s) by within-268 
subjects ANOVA (treatment x repetition), with planned comparisons for data from each repetition 269 
as described above. 270 
A power calculation conducted using G Power 
(27)
 suggested that a sample size of 24 would be 271 
adequate to have greater than an 80% chance of detecting the medium effect sizes demonstrated in 272 
previous research assessing the effect of resveratrol on NIRS parameters 
(10)
. 273 
 274 
 275 
 276 
 277 
 278 
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RESULTS 279 
NIRS parameters 280 
Total haemoglobin (total-Hb) 281 
A significant interaction was found between post-dose epoch and treatment (P <0.01) on the 282 
ANOVA of total-Hb data. Planned comparisons showed that, compared to placebo, the 250mg 283 
resveratrol treatment failed to elicit any modulation of total-Hb levels. However, following 250mg 284 
resveratrol combined with 20mg piperine, whilst there were no significant effects during the 285 
absorption period, levels of total haemoglobin were significantly raised for all task performance 286 
epochs (apart from 45, 51 and 79 minutes). Time-points 41, 49 and 61 were all significant at the .05 287 
level and the remainder at .01.  288 
 289 
Oxygenated haemoglobin (oxy-Hb) 290 
ANOVA showed that there was a significant interaction between the post-dose epoch and treatment 291 
(P <0.05). The pattern was similar to that seen with regards total-Hb, with no modulation seen 292 
following 250mg resveratrol, but significantly raised concentrations of oxy-Hb seen following 293 
250mg resveratrol with 20mg piperine (all epochs P <0.01, except 45, 49 and 51 which were P 294 
<0.05 and 79 which just failed to reach significance). 295 
 296 
Deoxygenated haemoglobin (deoxy-Hb) 297 
ANOVA showed that there was no significant main effect or interaction between time and treatment 298 
with regards deoxy-Hb. Planned comparisons, however, demonstrated a consistent pattern of 299 
significant effects which began to emerge during the end of the absorption phase and continued 300 
throughout the post-dose task period. After the 250mg resveratrol with 20mg piperine dose, levels 301 
of deoxy-Hb were significantly raised in comparison to placebo (during the absorption period 302 
epochs 27, 29, 33, 35 and 37 <0.05 and 39 <0.01; during post-dose task period all epochs <0.01 303 
apart from 77 which was <0.05).   304 
 305 
The mean data (± SEM) and the results of the planned comparisons for total-, and deoxy-Hb are 306 
represented in Figure 2.  307 
 308 
 309 
 310 
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 311 
Figure 2. Hemodynamic effects of 250mg resveratrol alone, and when co-supplemented with 20mg 312 
piperine, in healthy, young humans. Mean (±SEM), change from baseline, concentration changes in total 313 
levels of haemoglobin (total-Hb) and deoxygenated haemoglobin (deoxy-Hb) during a 40-min absorption 314 
period and subsequent 40-min of cognitive task performance following placebo (○), 250mg trans-resveratrol 315 
(●), and 250mg trans-resveratrol with 20mg piperine (▼). The study followed a cross-over design (n= 23 316 
per condition). Data are averaged across 2 minute epochs. A priori planned comparisons comparing data 317 
from each resveratrol group to placebo for each epoch were carried out with t-tests incorporating Mean 318 
Squares Error from an initial ANOVA. Significance on the planned comparisons is indicated by * (P< 0.05) 319 
and ** (P< 0.01).  320 
 321 
 322 
 323 
 324 
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Cognitive task performance and mood  325 
There were no significant, treatment related differences on any cognitive or mood measures. The 326 
raw baseline and change from baseline mean task scores and mood ratings can be found in tables 1 327 
and 2 respectively. 328 
 329 
Table 1. Effects of resveratrol on cognitive performance. Mean values with their standard errors. N= 23. 330 
T= treatment; R= repetition; RVIP= rapid visual information processing. *=P0·05, **=P0·01. 331 
Measure Treatment condition 
Task battery repetition 
Baseline 1 2 3 4 
7s Total 
(Number) 
250mg resveratrol 
30.72 
(2.66) 
1.54 
(0.82) 
1.72 
(0.74) 
1.89 
(0.71) 
1.59 
(1.06) 
250mg resveratrol 
with 20mg Piperine 
30.52 
(2.58) 
1.61 
(0.65) 
0.65 
(0.72) 
1.70 
(1.18) 
1.70 
(1.07) 
Placebo 
30.76 
(2.00) 
2.28 
(0.91) 
1.20 
(0.96) 
0.94 
(1.08) 
1.11 
(1.06) 
7s Correct 
(Number) 
250mg resveratrol 
28.85 
(2.75) 
1.20 
(1.02) 
1.98 
(0.94) 
1.54 
(0.83) 
0.80 
(1.16) 
250mg resveratrol 
with 20mg Piperine 
28.83 
(2.59) 
1.52 
(0.85) 
-0.04 
(0.94) 
0.39 
(1.25) 
0.57 
(1.13) 
Placebo 
28.85 
(2.04) 
1.94 
(1.12) 
0.89 
(1.11) 
0.11 
(1.43) 
0.98 
(1.29) 
7s Incorrect 
(Number) 
250mg resveratrol 
1.87 
(0.30) 
0.35 
(0.51) 
-0.26 
(0.37) 
0.35 
(0.38) 
0.70 
(0.55) 
250mg resveratrol 
with 20mg Piperine 
1.67 
(0.23) 
0.11 
(0.39) 
0.67 
(0.38) 
1.33 
(0.52) 
1.07 
(0.49) 
Placebo 
1.91 
(0.26) 
0.30 
(0.52) 
0.30 
(0.47) 
0.78 
(0.60) 
0.13 
(0.46) 
13s Total 
(Number) 
250mg resveratrol 
24.28 
(2.24) 
0.80 
(0.84) 
1.24 
(0.79) 
0.85 
(0.72) 
-0.02 
(0.78) 
250mg resveratrol 
with 20mg Piperine 
24.37 
(2.09) 
1.50 
(0.53) 
0.41 
(0.71) 
1.46 
(0.79) 
1.80 
(0.69) 
Placebo 
24.22 
(1.50) 
2.17 
(0.77) 
1.74 
(0.86) 
2.00 
(0.90) 
1.52 
(0.73) 
13s Correct 
(Number) 
250mg resveratrol 
22.22 
(2.25) 
0.70 
(0.88) 
-0.78 
(0.90) 
0.22 
(0.87) 
-1.17 
(0.98) 
250mg resveratrol 
with 20mg Piperine 
22.46 
(2.17) 
1.33 
(0.75) 
-1.15 
(1.26) 
-0.11 
(1.25) 
1.07 
(0.87) 
Placebo 
21.83 
(1.60) 
3.26 
(0.83) 
0.78 
(1.41) 
1.17 
(1.20) 
1.09 
(1.03) 
13s Incorrect 
(Number) 
250mg resveratrol 
2.04 
(0.23) 
0.13 
(0.40) 
2.04 
(1.00) 
0.65 
(0.51) 
1.17 
(0.47) 
250mg resveratrol 
with 20mg Piperine 
1.89 
(0.36) 
0.11 
(0.44) 
1.59 
(0.94) 
1.59 
(0.63) 
0.76 
(0.73) 
Placebo 
2.39 
(0.36) 
-1.09 
(0.33) 
0.96 
(0.84) 
0.78 
(0.53) 
0.44 
(0.58) 
17s Total 
(Number) 
250mg resveratrol 
19.50 
(1.68) 
1.54 
(0.58) 
1.50 
(0.56) 
2.59 
(0.55) 
2.67 
(0.56) 
250mg resveratrol 
with 20mg Piperine 
19.98 
(1.61) 
0.67 
(0.72) 
0.72 
(0.72) 
1.41 
(0.70) 
2.63 
(0.64) 
Placebo 
19.39 
(1.28) 
1.39 
(0.60) 
0.91 
(0.55) 
1.57 
(0.58) 
1.83 
(0.51) 
13 
 
17s Correct 
(Number) 
250mg resveratrol 
17.22 
(1.68) 
1.39 
(0.71) 
1.48 
(0.81) 
2.35 
(0.75) 
1.09 
(1.13) 
250mg resveratrol 
with 20mg Piperine 
17.78 
(1.61) 
0.39 
(0.63) 
0.44 
(0.86) 
0.87 
(0.90) 
2.13 
(0.76) 
Placebo 
16.80 
(1.29) 
1.72 
(0.62) 
1.37 
(0.68) 
1.15 
(0.95) 
1.89 
(0.59) 
17s Incorrect 
(Number) 
250mg resveratrol 
2.28 
(0.28) 
0.15 
(0.41) 
0.02 
(0.47) 
0.24 
(0.52) 
1.54 
(1.09) 
250mg resveratrol 
with 20mg Piperine 
2.17 
(0.29) 
0.30 
(0.42) 
0.30 
(0.50) 
0.57 
(0.42) 
0.52 
(0.37) 
Placebo 
2.57 
(0.27) 
-0.30 
(0.37) 
-0.44 
(0.45) 
0.44 
(0.67) 
-0.04 
(0.36) 
N-Back 
Accuracy (%) 
250mg resveratrol 
93.38 
(1.17) 
-0.34 
(0.97) 
-1.02 
(1.05) 
-0.92 
(1.08) 
-0.05 
(1.00) 
250mg resveratrol 
with 20mg Piperine 
94.40 
(0.91) 
-2.03 
(1.02) 
-1.84 
(1.09) 
-0.29 
(0.89) 
-1.45 
(1.27) 
Placebo 
94.40 
(0.74) 
-1.26 
(1.08) 
-1.55 
(0.92) 
-2.61 
(1.13) 
01.45 
(0.93) 
N-Back 
Reaction Time 
(msec) 
250mg resveratrol 
1540.45 
(145.80) 
-291.04 
(48.75) 
-345.87 
(53.98) 
-312.95 
(52.58) 
-398.24 
(58.12) 
250mg resveratrol 
with 20mg Piperine 
1476.26 
(189.03) 
-243.72 
(67.01) 
-287.30 
(77.69) 
-375.74 
(94.44) 
-292.16 
(70.96) 
Placebo 
1475.04 
(161.35) 
-194.12 
(34.69) 
-149.39 
(70.65) 
-264.79 
(81.89) 
-271.44 
(57.14) 
RVIP correct 
(%) 
250mg resveratrol 
71.06 
(3.76) 
0.41 
(2.98) 
-4.48 
(2.44 ) 
-7.47 
(3.73) 
-7.76 
(2.58) 
250mg resveratrol 
with 20mg Piperine 
65.81 
(4.00) 
3.76 
(2.32) 
1.31 
(3.39) 
-4.36 
(3.39) 
-1.68 
(3.51) 
Placebo 
69.16 
(3.90) 
1.50 
(2.25) 
-7.38 
(3.65) 
-7.47 
(2.51) 
-6.66 
(3.40) 
RVIP Reaction 
Time (msec) 
250mg resveratrol 
494.24 
(8.87) 
5.10 
(5.73) 
0.61 
(8.76) 
1.18 
(7.86) 
3.90 
(9.57) 
250mg resveratrol 
with 20mg Piperine 
501.68 
(9.46) 
-7.17 
(8.07) 
2.06 
(10.99) 
-2.86 
(10.18) 
-4.06 
(9.98) 
Placebo 
499.22 
(0.13) 
-7.11 
(7.30) 
3.79 
(10.20) 
0.48 
(13.14) 
1.89 
(8.38) 
 332 
Table 2. Effects of 250mg resveratrol alone and when co-supplemented with 20mg piperine on mood in 333 
healthy, young human subjects. Mean values with their standard errors. N= 23. T= treatment; R= 334 
repetition. *=P0·05, **=P0·01. 335 
Measure Treatment condition Baseline Post-dose 
ANOVA 
Effect F P 
Alert 
250mg 
resveratrol 
50.83 
(3.79) 
-6.65 
(5.44) T .767 .470 
250mg resveratrol 
with 20mg Piperine 
49.13 
(3.78) 
4.43 (4.07) R .359 .555 
Placebo 
51.57 
(4.08) 
-4.87 
(4.68) 
T*R 3.28 .047* 
Jittery 
250mg 
resveratrol 
16.83 
(2.91) 
19.78 
(5.40) T .532 .591 
250mg resveratrol 
with 20mg Piperine 
18.61 
(3.33) 
20.48 
(4.95) 
R 25.79 <.001** 
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Placebo 
15.39 
(2.54) 
20.87 
(4.73) 
T*R .022 .979 
Mental 
Fatigue 
250mg 
resveratrol 
28.96 
(4.69) 
35.65 
(6.18) T .839 .439 
250mg resveratrol 
with 20mg Piperine 
27.48 
(4.86) 
32.48 
(5.93) 
R 45.47 <.001** 
Placebo 
26.22 
(4.10) 
33.74 
(6.11) 
T*R .147 .864 
Overall 
Mood 
250mg 
resveratrol 
62.87 
(3.46) 
-16.13 
(4.48) T 2.66 .081 t 
250mg resveratrol 
with 20mg Piperine 
64.48 
(3.04) 
-12.78 
(3.60) 
R 25.87 <.001** 
Placebo 
67.35 
(2.71) 
-13.74 
(2.97) 
T*R .321 .727 
Relaxed 
250mg 
resveratrol 
62.91 
(2.67) 
-24.52 
(5.62) T .566 .572 
250mg resveratrol 
with 20mg Piperine 
60.35 
(3.29) 
-14.13 
(6.00) 
R 20.70 <.001** 
Placebo 
62.52 
(1.98) 
-20.61 
(4.44) 
T*R 1.79 .179 
Tense 
250mg 
resveratrol 
25.48 
(3.29) 
25.74 
(6.35) T 2.32 .110 
250mg resveratrol 
with 20mg Piperine 
23.87 
(3.28) 
26.35 
(6.40) 
R 26.08 <.001** 
Placebo 
19.83 
(3.02) 
25.30 
(5.37) 
T*R .016 .984 
Tired 
250mg 
resveratrol 
47.09 
(4.51) 
14.57 
(5.33) T .405 .669 
250mg resveratrol 
with 20mg Piperine 
50.74 
(5.05) 
4.04 (3.92) R 5.96 .023* 
Placebo 
45.57 
(4.42) 
11.52 
(6.39) 
T*R 1.72 .191 
 336 
Blood pressure 337 
No significant, treatment related differences were observed on pulse rate, diastolic or systolic blood 338 
pressure. Raw baseline and change from baseline post-dose BP readings are displayed in table 3. 339 
 340 
Table 3. Effects of 250mg resveratrol alone and when co-supplemented with 20mg piperine on blood 341 
pressure in healthy, young human subjects. Mean values with their standard errors in brackets. 342 
Measure Treatment condition 
Task battery repetition ANOVA 
Baseline PD 1 PD 2 Effect F P 
Systolic Blood 
Pressure 
(mmHg) 
250mg resveratrol 
112 
(1.98) 
2.35 
(1.77) 
4.87 
(1.21) Tr .621 .542 
250mg resveratrol 
with 20mg Piperine 
114.17 
(1.98) 
1.39 
(1.26) 
4.90 
(1.72) 
Ti 9.61 .005** 
Placebo 
113.22 
(2.31) 
-0.04 
(1.78) 
3.39 
(2.13) 
Tr*Ti .089 .915 
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Diastolic Blood 
Pressure 
(mmHg) 
250mg resveratrol 
75.65 
(1.66) 
2.57 
(0.90) 
4.17 
(0.96) Tr 3.68 .045* 
250mg resveratrol 
with 20mg Piperine 
75.09 
(1.62) 
4.83 
(1.38) 
4.70 
(1.65) 
Ti .628 .437 
Placebo 
76.91 
(2.48) 
-0.17 
(2.08) 
0.65 
(1.77) 
Tr*Ti .258 .724 
Pulse Rate 
(BPM) 
250mg resveratrol 
68.43 
(2.48) 
-0.83 
(1.07) 
-2.26 
(1.51) Tr 1.77 .192 
250mg resveratrol 
with 20mg Piperine 
67.91 
(2.14) 
0.35 
(1.87) 
-3.74 
(3.78) 
Ti 3.38 .080 t 
Placebo 
70.87 
(2.29) 
-3.78 
(1.63) 
-6.87 
(1.63) 
Tr*Ti .368 .584 
PD, post-dose; Tr, treatment; Ti, time; bpm, beats per min.; t, trend. There were significant main effects for 343 
Tr and Ti: *P,0·05, **P,0·01. † Baseline, immediately before treatment; PD 1, 40min post-dose and 344 
immediately before post-dose tasks; PD 2, 95 min post-dose and immediately after post-dose tasks. 345 
 346 
Bioavailability 347 
No resveratrol (in any form) was found in baseline samples, indicating that all volunteers did not 348 
consume resveratrol before the study. Following oral intervention with 250mg of resveratrol, 349 
plasma concentrations of total resveratrol metabolites ranged from 2-18.2μM, varying between 350 
individuals and treatments. However, no aglycone trans- or cis-resveratrol was quantifiable in 351 
plasma. Resveratrol 3-O-sulfate was the predominant metabolite in all volunteers, contributing 59-352 
81% of total metabolites. The 4’- and 3-O-glucuronide forms made roughly equal contributions to 353 
the remaining metabolites in circulation. Cmax was typically achieved at 90 minutes. Resveratrol 354 
conjugates were present in plasma as both trans- and cis-isomers, varying between individuals. The 355 
average Cmax trans- :cis-ratios for resveratrol 3-O-sulfate and resveratrol 3-O-glucuronide following 356 
consumption of all trans-resveratrol were 4.7±5.6 (ranging 1.2-15.9) and 5.1±5.6 (ranging 0.94-357 
18.8), respectively. Cis-resveratrol 4’-O-glucuronide was observable within some, but not all 358 
subjects. Extraction efficiency tests did not indicate significant induction of isomerization during 359 
sample handling, suggesting that this conversion occurs in vivo. 360 
Whilst average concentrations at Cmax for resveratrol 3-O-sulfate, 4’-O-glucuronide and 3-O-361 
glucuronide appeared lower following piperine co-supplementation compared to resveratrol alone, 362 
there was no significant difference between treatments. Similarly, there was no significant 363 
difference for area under the curve values, and Tmax was not significantly changed between 364 
treatments.  365 
Mean plasma concentrations of trans-resveratrol 3-O-sulfate and combined 4’-O-glucuronide and 3-366 
O-glucuronide metabolites at pre-treatment and at 45-, 90- and 120 minute post-dose time-points, 367 
for both treatment conditions, are shown in Figure 3. 368 
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 369 
Fig. 3. Plasma bioavailability of resveratrol metabolites following (a) the administration of 250mg 370 
trans-resveratrol alone and (b) the administration of 250mg trans-resveratrol with 20mg piperine in 371 
healthy, young human subjects. Values are means (n 6), with their standard errors represented by 372 
vertical bars.     , Concentration of resveratrol 3-O-sulphate;    , combined concentrations of 373 
resveratrol 40-O-glucuronide and resveratrol 3-O-glucuronide.  374 
 375 
 376 
DISCUSSION 377 
The current study demonstrates that the well-established bioenhancer piperine, is also able to 378 
increase the bioefficacy of the polyphenol resveratrol when co-supplemented in healthy humans. 379 
Whereas 250mg orally administered trans-resveratrol had no significant effects on overall CBF 380 
(total-Hb) during cognitive task demands, co-administration of the same dose of resveratrol with 381 
20mg piperine resulted in significantly increased CBF for the duration of the 40 minute post-dose 382 
task period. The findings with regards resveratrol alone in this respect are broadly in line with the 383 
dose response pattern of CBF evinced following resveratrol in a previous study; in which 250mg 384 
was largely ineffective 
(10)
. Despite this piperine-mediated enhancement of resveratrol’s CBF effects 385 
however, there were no significant treatment related differences in performance of the cognitive 386 
tasks nor on blood pressure/heart rate, or participants’ ratings of mood for either active treatment.  387 
The pattern of hemodynamic effects of resveratrol seen here, when enhanced with piperine, is 388 
exactly in line with the aforementioned previous resveratrol intervention study following a 500mg 389 
dose 
(10)
. This pattern is seen as significantly higher levels of total- and oxy-Hb, alongside deoxy-390 
Hb, during the post-dose cognitive task period and represents increased CBF and oxygen utilization 391 
respectively. This hemodynamic response is dissimilar to that seen during cognitive task 392 
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performance alone. Here total- and oxy-Hb typically rise alongside a concomitant decline in deoxy-393 
Hb levels 
(28)
, with this phenomenon predicated on the fact that neural activation instigates an 394 
increase in CBF which is greater than the metabolic rate of oxygen extraction/utilization. As such, 395 
deoxy-Hb can be observed to decrease during cognitive performance 
(29)
. The different deoxy-Hb 396 
response seen following resveratrol is likely predicated on indirect effects on mitochondrial 397 
phosphorylation. In support of this, Lagouge et al. 
(30)
 report that, in mice, supplementation with 398 
400mg/kg/day resveratrol, for 15-weeks, significantly increased mitochondrial structures and 399 
enzymatic activity. This resulted in a significant increase in O2 consumption and VO2 max rate and 400 
was observed to increase running time and tolerance to cold. In terms of mechanisms, resveratrol is 401 
able to interact with the sirtuin (‘silent information regulator’: SIRT) system; a class of proteins 402 
involved with multifarious biological processes that has received a great amount of attention over 403 
the past decade in relation to life-extension 
(31)
. Of importance here, SIRT is implicated in the 404 
deacetylation of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α); a 405 
gene which controls mitochondrial biogenesis and function 
(32)
, and, whilst the oxygenation effects 406 
in the above study in rodents followed chronic consumption, these mechanisms would explain the 407 
O2 consumption effects seen here; represented by deoxy-Hb.  408 
Interestingly, in light of significant CBF effects occurring only with the resveratrol/piperine 409 
combination, no significant differences were found in plasma levels of resveratrol between 410 
treatments. In both treatment conditions, resveratrol metabolites were present in plasma across the 411 
post-dose cognitive task period and the parent compound was un-quantifiable at all time points. 412 
However, contrary to the hypothesis of piperine-induced bioenhancement, the pattern of effects here 413 
actually suggests inhibition rather than enhancement of plasma levels, e.g. the Cmax of total 414 
metabolites after 250mg resveratrol was 9.98µM compared to 4.82µM in the piperine co-415 
supplemented condition. Piperine also appeared to be inhibiting the transit of resveratrol; evidenced 416 
by the tmax of metabolites in the 250mg resveratrol condition occurring at the 90 minute sample 417 
time-point compared to the 120 minute time-point in the co-supplemented condition and the 418 
observation of metabolite levels reducing at the 120 minute time-point in the 250mg resveratrol 419 
condition and not in the co-supplemented group. Nevertheless, this pattern of effects evinced no 420 
significant differences between treatment groups which suggests two possibilities; either piperine is 421 
able to exert CBF effects independently of resveratrol or, alternatively, it potentiates the effects of 422 
resveratrol seen previously on CBF.  423 
Taking the first of those possibilities then, it is notable that only 1 study 
(33)
 exists to suggest that 424 
piperine is capable of interacting with NO and that this was the inducible NO synthase isoform 425 
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(iNOS) which is stimulated in response to immunological stimuli 
(34)
 and is not associated with 426 
cerebral vasorelaxation and increased blood flow. No data exist to suggest that piperine is capable 427 
of affecting oxygenation, or indeed any other factor relevant to this study, and, taken together, this 428 
precluded the need for a piperine-only treatment condition here. The exception here is a small 429 
amount of literature in rats which suggests that chronic (up to 4-weeks) piperine supplementation 430 
might improve aspects of performance; although this appears to be mostly related to mood 431 
augmentation rather than enhanced cognition per say 
(35-37)
. Nevertheless, future studies may 432 
warrant investigation of the efficacy of piperine alone on these parameters, in humans, in order to 433 
clarify this issue. 434 
In light of a lack of evidence to suggest that piperine has any influence on parameters relevant to 435 
CBF, and in the face of no significant modulation of CBF in the resveratrol condition alone (a 436 
finding mirrored in Kennedy et al. 
(10)
 with the same dose) it seems more likely that piperine is 437 
increasing the bioefficacy of resveratrol by potentiating its vasorelaxatory properties. In support of 438 
this, resveratrol is a well validated vasorelaxatory mediator 
(7)
 and, at a higher dose (500mg), can 439 
increase CBF in healthy humans 
(10)
.  440 
Of the potential mechanisms to explain the efficacy enhancing effects of piperine, one possibility is 441 
that piperine is able to enhance the activity of resveratrol, the neuronal vasculature, and/or some 442 
other factor relevant to CBF via thermogenic properties. As evidence of piperines’ heat-proffering 443 
properties, specifically in neural tissue, Reanmongkol et al. 
(38)
 report on the ability of piperine to 444 
stimulate activity of ATPase (but inhibition of oxidative phoshorylation) which produces heat as a 445 
by-product 
(39)
. Thermogenic increases in tissue activity have previously been proposed as an 446 
explanation for piperine-mediated increases in plasma beta-carotene levels in humans 
(13)
 via 447 
increasing the absorption rate of the intestinal epithelium and, as a mechanism, could exist without 448 
piperine evincing an overall increase in resveratrol bioavailability: a phenomenon observed 449 
previously 
(11-14)
 but not replicated here.  450 
In terms of behavioural effects, the results of the current study are in line with previous findings: i.e. 451 
a lack of any effect of a 250mg dose of resveratrol with regards cognitive task performance 
(10)
. One 452 
of the primary reasons for utilizing piperine here was to investigate whether this well established 453 
bioenhancer of polyphenols might also evince an enhancement of resveratrol’s bioefficacy; 454 
especially in terms of cognitive function due to the null effects reported previously. However, 455 
whilst the increase in CBF during task performance was potentiated by piperine, the pattern was 456 
largely the same as that seen following a larger dose of resveratrol (500mg in 
(10)
) where cognitive 457 
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effects were also lacking. It would therefore appear that acute increases in CBF are not sufficient, in 458 
themselves, to alter cognitive function in the young, healthy cohorts utilized here and previously. 459 
However, it may be the case that longer-term supplementation is required, or indeed that the effects 460 
might translate into cognitive benefits in populations showing age- or pathology-related decrements 461 
in CBF and cognitive function.  462 
In conclusion, this is the first study to report that piperine co-supplementation enhances the 463 
bioefficacy of resveratrol with regards CBF effects in healthy humans, but not cognitive 464 
performance, and does this without altering the overall bioavailability of resveratrol in vivo.  465 
 466 
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